Introduction
In the past 15 years an increasing number of case reports linking thyrotoxicosis with hypercalcaemia have appeared in the literature. The combination, though forming only a small proportion of all patients with thyrotoxicosis, can result in a serious situation arising from acute and potentially fatal hypercalcaemic complications. We have recently studied three cases of hypercalcaemic thyrotoxicosis. In each case there was intractable vomiting, which in one case could be relieved only by lowering the plasma calcium concentration by intravenous inorganic phosphate infusion. In the other two cases treatment with carbimazole alone resulted in cessation of vomiting and lowered the plasma calcium level to within normal limits.
Case 1
A 33-year-old man gave a history of recurrent vomiting for 24 hours. Three weeks earlier he had felt nauseated for several days and had been transiently jaundiced. The relevant abnormal findings were hepatosplenomegaly, mild icterus, and a serum bilirubin concentration of 2-5 mg./100 ml.; there was no evidence of haemolysis. Plasma calcium levels were consistently raised ( Fig. 1) .
Despite continued vomiting polyuria persisted with increasing dehydration. Further inquiry showed that he had lost over 20 lb. (9 kg.) in weight during the preceding six months. No direct thyroid function test was done at this time, but on the basis of the history and biochemical findings (Table I) Case 3
A 24-year-old married woman developed a puerperal schizoaffective psychosis. The response to electric convulsion therapy, insulin therapy, and phenothiazines was poor. Some weeks after admission she began to vomit up to four times a day. Her weight fell by 28 lb. (12-7 kg.) in the ensuing six weeks. Thyroid function tests confirmed thyrotoxicosis (Table I ). The plasma calcium concentration was 13-0 mg./100 ml. Treatment with carbimazole 10 mg. eight-hourly was started and after a few days the vomiting stopped. Plasma calcium concentration returned to normal within four weeks. Six months after diagnosis the patient remained well and normocalcaemic on maintenance doses of carbimazole.
Discussion
Vomiting in thyrotoxicosis has long been recognized (Lahey. 1932) , though only comparatively recently has the occasional dominance of this symptom been emphasized (Nikkila and Pitkanen, 1960 (Werner, 1962) . Hypercalcaemia, though not always the cause, should be suspected whenever vomiting complicates thyrotoxicosis (Nikkila and Pitkanen, 1960 (Noble and Borg, 1936; Wijnbladh, 1937; Miller and Evans, 1942; Koenig et al., 1957; Epstein et al., 1958; Hubble, 1958) . In half the cases the hypercalcaemia was attributed to thyrotoxicosis alone, but in the remainder there was associated hyperparathyroidism. In the past decade more than 20 further cases of ooexistent thyrotoxicosis and hyperparathyroidism have been reported (Breuer and McPherson, 1966; Ahuja and Chopra, 1968) . This has led to the unwarranted assumption that finding unequivocal hypercalcaemia in a patient with thyrotoxicosis should always lead to a search for a parathyroid adenoma (Klotz et al., 1968) despite the evidence that a tendency towards hypercalcaemia is normal in uncomplicated thyrotoxicosis (Nikkila and Pitkanen, 1960; Baxter and Bondy, 1966; Frizel et al., 1967) .
That thyrotoxicosis per se can alter calcium metabolism has been known for many years. In 1891 von Recklinghausen described the case of a young woman suffering from osteitis fibrosa cystica and thyrotoxicosis. More recently Follis (1953) observed pathological changes resembling osteitis fibrosa in each of 20 thyrotoxic subjects examined at necropsy. Aub et al. (1929) observed consistently increased faecal and urinary loss of calcium in thyrotoxic patients despite normocalcaemia. The plasma ionized calcium concentration has been shown to be consistently raised in thyrotoxicosis (Frizel et al., 1967) . A reduction in the protein-bound calcium, consequent on hypoalbuminaemia (Adams et al., 1967; Klotz et al., 1968) accounts for the comparative infrequency of overt hypercalcaemia.
In about 100/,, of cases the rise in ionized calcium corcentration more than offsets the reduction in plasma proteinbound calcium concentration and hypercalcaemia results (Nikkila and Pitkanen, 1960; Baxter and Bondy, 1966) . Occasionally this is severe enough to cause nausea, vomiting, polyuria, dehydration, and hypercalcaemic nephropathy, all of which were seen in one or more of our three patients.
The cause of hypercalcaemia in thyrotoxicosis is still obscure. Morbid anatomical (Follis, 1953) , clinical, and kinetic studies in patients with thyrotoxicosis (Krane et al., 1956) suggest that there is increased bone catabolism leading to increased calcium mobilization. Pribek and Meade (1957) have suggested that hypercalcaemia will occur only when there is concomitant failure to suppress parathyroid hormone secretion in the face of a rise of plasma calcium concentration. Nevertheless, hypercalcaemia in thyrotoxicosis probably occurs despite parathyroid suppression. In a case of hypercalcaemic thyrotoxicosis recently reported (Buckle et al., 1969) , plasma immunoreactive parathyroid hormone concentration was unrecordably low (under 0.1 ng./ml.). Later, when euthyroidism and normocalcaemia had been re-established, the plasma immunoreactive parathyroid hormone concentration was found to be within the normal range (0-1 to 0.25 ng./ml.). The calcitonin content of the hyperplastic thyroid gland is reputedly lower than in the normal thyroid gland (Aliapoulios et al., 1966; Klotz et al., 1968) , and impaired secretion of calcitonin could conceivably account for the appearance of hypercalcaemia in thyrotoxicosis.
Treatment by conventional means is usually sufficient in thyrotoxicosis complicated by overt hypercalcaemia, but in rare cases more direct measures, aimed at lowering the plasma calcium level, may have to be used. Search for a second pathological condition to explain the hypercalcaemia is unnecessary and may be confusing. For example, the cortisone acetate suppression test has been reported as positive (Sataline et al., 1962) or negative (David et al., 1962) in thyrotoxicosis.
The time taken for the complete return of plasma calcium levels to normal after initiating antithyroid therapy varies. children. Thirteen presented with bone or joint infection (Table I) , 17 had a variety of infections caused by penicillinresistant Staphylococcus aureus species, and 20 suffered from pneumonia. The 17 miscellaneous staphylococcol infections were: cellulitis 4, wound infection 5, suppurative lymphadenopathy 3, chronic bronchitis 2, breast abscess 1, and skin infection 2. The antibiotic was administered in capsules at six-hourly intervals as clindamycin hydrochloride hydrate (Dalacin C). The six-hourly dose was 300 mg. for adults, 150 mg. for children under 12 years, and 75 mg. for babies, who were given the antibiotic in powder form in milk. Parenteral preparations of clindamycin are not available at present, and four patients who were judged on clinical grounds to be septicaemic were given intramuscular lincomycin for the first three to four days of their illness. Septicaemia was subsequently confirmed in all four patients. The duration of chndamycin therapy ranged from 7 to 187 days, depending on the severity and chronicity of the infection. Liver function tests, full haematology, urine analysis and measurement of serum urea and electrolytes were performed at least once during treatment in all adults and most children. The patients were observed for clinical evidence of possible untoward reactions to the drug.
Before treatment was started appropriate specimens were taken for bacteriological examination. The clindamycin sensitivity of all organisms cultured was determined with a 2-,ug. disc. The disc sensitivities to clindamycin of 500 Staph. aureus and 100 Haemophilus influenzae isolates were also recorded. The minimum inhibitory concentrations for 34 Staph. aureus strains were determined by the tube dilution technique.
